Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
The aim of this multicenter randomized phase II trial is to determine the efficacy of sorafenib and irinotecan combination versus irinotecan monotherapy or versus sorafenib monotherapy in metastatic colorectal cancer patients with KRAS mutated tumors after failure of all active drugs known to be effective.
Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
DRUG: Sorafenib and irinotecan combination|DRUG: Sorafenib monotherapy|DRUG: Irinotecan monotherapy
Non-progression rate, To evaluate the non-progression rate at 2 months according to RECIST criteria (Version 1.1), At 2 months
Disease control rate, According to RECIST criteria (Version 1.1), At 2 months|Treatment-related toxicity, According to NCI CTC V4.0, At 6 months|Overall survival, Overall survival is defined as the time from the date of inclusion to the date of death from any cause., At 6 months|Quality of life questionnaire, Using the EORTC QLQ-C30 questionnaire, 6 months|Progression Free Survival, Progression Free Survival is defined as the time from the date of inclusion to first documentation of objective tumor progression or to death due to progression., At 6 months|Response rate, According to RECIST criteria (Version 1.1), At 2 months
Cmax and Tmax of sorafenib and irinotecan, Up to 3 months
The aim of this multicenter randomized phase II trial is to determine the efficacy of sorafenib and irinotecan combination versus irinotecan monotherapy or versus sorafenib monotherapy in metastatic colorectal cancer patients with KRAS mutated tumors after failure of all active drugs known to be effective.